-
1
-
-
79960347241
-
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: A 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients
-
Horie Y, Kanada S, Watada H, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. Clin Ther. 2011;33:973-989.
-
(2011)
Clin Ther
, vol.33
, pp. 973-989
-
-
Horie, Y.1
Kanada, S.2
Watada, H.3
-
2
-
-
72049121944
-
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
-
Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2010;19:133-140.
-
(2010)
Expert Opin Investig Drugs
, vol.19
, pp. 133-140
-
-
Deacon, C.F.1
Holst, J.J.2
-
3
-
-
79955022470
-
1c after 4 weeks of treatment in patients with type 2 diabetes mellitus
-
Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:542-550.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 542-550
-
-
Forst, T.1
Uhlig-Laske, B.2
Ring, A.3
Ritzhaupt, A.4
Graefe-Mody, U.5
Dugi, K.A.6
-
4
-
-
78851472527
-
Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial
-
Del PS, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13:258-267.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 258-267
-
-
Del, P.S.1
Barnett, A.H.2
Huisman, H.3
Neubacher, D.4
Woerle, H.J.5
Dugi, K.A.6
-
5
-
-
83455210130
-
Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes
-
Forst T, Pfutzner A. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin Pharmacother. 2012;13:101-110.
-
(2012)
Expert Opin Pharmacother
, vol.13
, pp. 101-110
-
-
Forst, T.1
Pfutzner, A.2
-
6
-
-
81255150186
-
Linagliptin for the treatment of type 2 diabetes
-
Del Prato S. Linagliptin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2011;12:2759-2762.
-
(2011)
Expert Opin Pharmacother
, vol.12
, pp. 2759-2762
-
-
del Prato, S.1
-
7
-
-
79961222810
-
Pharmacology of dipeptidyl peptidase-4 inhibitors: Similarities and differences
-
Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71:1441-1467.
-
(2011)
Drugs
, vol.71
, pp. 1441-1467
-
-
Baetta, R.1
Corsini, A.2
-
8
-
-
83455244389
-
A review of gliptins in 2011
-
Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012;13:81-99.
-
(2012)
Expert Opin Pharmacother
, vol.13
, pp. 81-99
-
-
Scheen, A.J.1
-
9
-
-
78249262065
-
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects
-
Retlich S, Duval V, Ring A, et al. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin Pharmacokinet. 2010;49:829-840.
-
(2010)
Clin Pharmacokinet
, vol.49
, pp. 829-840
-
-
Retlich, S.1
Duval, V.2
Ring, A.3
-
10
-
-
51849103389
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers
-
Huttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008;48:1171-1178.
-
(2008)
J Clin Pharmacol
, vol.48
, pp. 1171-1178
-
-
Huttner, S.1
Graefe-Mody, E.U.2
Withopf, B.3
Ring, A.4
Dugi, K.A.5
-
11
-
-
80051653327
-
A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects
-
Graefe-Mody U, Giessmann T, Ring A, Iovino M, Woerle HJ. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther. 2011;33:1096-1103.
-
(2011)
Clin Ther
, vol.33
, pp. 1096-1103
-
-
Graefe-Mody, U.1
Giessmann, T.2
Ring, A.3
Iovino, M.4
Woerle, H.J.5
-
12
-
-
67649998759
-
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
-
Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11:786-794.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 786-794
-
-
Heise, T.1
Graefe-Mody, E.U.2
Huttner, S.3
Ring, A.4
Trommeshauser, D.5
Dugi, K.A.6
-
13
-
-
77950197593
-
The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans
-
Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010; 38:667-678.
-
(2010)
Drug Metab Dispos
, vol.38
, pp. 667-678
-
-
Blech, S.1
Ludwig-Schwellinger, E.2
Grafe-Mody, E.U.3
Withopf, B.4
Wagner, K.5
-
14
-
-
84872361490
-
-
[Trajenta product information]. Ingelheim Am Rhein: Boehringer Ingelheim GmbH, Accessed March 13, 2012
-
[Trajenta product information]. Ingelheim am Rhein: Boehringer Ingelheim GmbH. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002110/WC500115745.pdf. Accessed March 13, 2012.
-
-
-
-
15
-
-
37349073397
-
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
-
Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem. 2007;50:6450-6453.
-
(2007)
J Med Chem
, vol.50
, pp. 6450-6453
-
-
Eckhardt, M.1
Langkopf, E.2
Mark, M.3
-
16
-
-
79958230306
-
Linagliptin: A novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy
-
Barnett AH. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Adv Ther. 2011;28:447-459.
-
(2011)
Adv Ther
, vol.28
, pp. 447-459
-
-
Barnett, A.H.1
-
17
-
-
84859438114
-
Safety and tolerability of linagliptin: A pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus
-
Schernthaner G, Barnett AH, Emser A, et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14:470-478.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 470-478
-
-
Schernthaner, G.1
Barnett, A.H.2
Emser, A.3
-
18
-
-
79955712959
-
Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects
-
Graefe-Mody U, Rose P, Ring A, Zander K, Iovino M, Woerle HJ. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metab Pharmacokinet. 2011;26:123-129.
-
(2011)
Drug Metab Pharmacokinet
, vol.26
, pp. 123-129
-
-
Graefe-Mody, U.1
Rose, P.2
Ring, A.3
Zander, K.4
Iovino, M.5
Woerle, H.J.6
-
19
-
-
77957665412
-
Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers
-
Graefe-Mody EU, Jungnik A, Ring A, Woerle HJ, Dugi KA. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. Int J Clin Pharmacol Ther. 2010;48:652-661.
-
(2010)
Int J Clin Pharmacol Ther
, vol.48
, pp. 652-661
-
-
Graefe-Mody, E.U.1
Jungnik, A.2
Ring, A.3
Woerle, H.J.4
Dugi, K.A.5
-
20
-
-
67650799130
-
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
-
Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009;25:1963-1972.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 1963-1972
-
-
Graefe-Mody, E.U.1
Padula, S.2
Ring, A.3
Withopf, B.4
Dugi, K.A.5
-
21
-
-
81855194761
-
Safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of randomized clinical trials
-
Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27(Suppl 3):57-64.
-
(2011)
Curr Med Res Opin
, vol.27
, Issue.SUPPL. 3
, pp. 57-64
-
-
Monami, M.1
Dicembrini, I.2
Martelli, D.3
Mannucci, E.4
-
22
-
-
84861693987
-
Pharmacokinetics of linagliptin in subjects with hepatic impairment
-
Graefe-Mody U, Rose P, Retlich S, et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012;74: 75-85.
-
(2012)
Br J Clin Pharmacol
, vol.74
, pp. 75-85
-
-
Graefe-Mody, U.1
Rose, P.2
Retlich, S.3
-
23
-
-
80052530183
-
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*)
-
Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab. 2011;13:939-946.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 939-946
-
-
Graefe-Mody, U.1
Friedrich, C.2
Port, A.3
-
24
-
-
84855481995
-
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
-
Johansen OE, Neubacher D, vonEynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3.
-
(2012)
Cardiovasc Diabetol
, vol.11
, pp. 3
-
-
Johansen, O.E.1
Neubacher, D.2
Voneynatten, M.3
Patel, S.4
Woerle, H.J.5
-
25
-
-
80051785333
-
DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice
-
Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2011;58:157-166.
-
(2011)
J Cardiovasc Pharmacol
, vol.58
, pp. 157-166
-
-
Ta, N.N.1
Schuyler, C.A.2
Li, Y.3
Lopes-Virella, M.F.4
Huang, Y.5
-
26
-
-
80052719404
-
Treatment of streptozotocin-induced diabetic rats with alogliptin: Effect on vascular and neural complications
-
Article ID 810469 2011
-
Davidson EP, Coppey LJ, Dake B, Yorek MA. Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications. Exp Diabetes Res. 2011;2011:Article ID 810469.
-
(2011)
Exp Diabetes Res
-
-
Davidson, E.P.1
Coppey, L.J.2
Dake, B.3
Yorek, M.A.4
-
27
-
-
84857903646
-
DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
-
Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis. Adv Ther. 2012;29: 14-25.
-
(2012)
Adv Ther
, vol.29
, pp. 14-25
-
-
Monami, M.1
Lamanna, C.2
Desideri, C.M.3
Mannucci, E.4
-
28
-
-
78649691630
-
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study
-
Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65-74.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 65-74
-
-
Taskinen, M.R.1
Rosenstock, J.2
Tamminen, I.3
-
29
-
-
79953174825
-
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo-controlled study
-
Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:653-661.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 653-661
-
-
Gomis, R.1
Espadero, R.M.2
Jones, R.3
Woerle, H.J.4
Dugi, K.A.5
-
30
-
-
80053072352
-
Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24-week randomized study
-
Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011;28:1352-1361.
-
(2011)
Diabet Med
, vol.28
, pp. 1352-1361
-
-
Owens, D.R.1
Swallow, R.2
Dugi, K.A.3
Woerle, H.J.4
|